Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Stoke Therapeutics has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2024.
Stoke Therapeutics's investors include RA Capital Management, Cormorant Asset Management, Janus Henderson Investors, Perceptive Advisors, Redmile Group.
Stoke Therapeutics is headquartered in Bedford, United States.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Stoke Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Stoke Therapeutics — Funding & Investors." VCBacked, March 27, 2024, https://www.vcbacked.co/company/stoke-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Stoke Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/stoke-therapeutics
{{cite web |title=Stoke Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/stoke-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated